AcquisitionsMay 8, 2026, 04:23 PM
Gyre Therapeutics Acquires Cullgen; Q1 Net Loss $(8.69)M
AI Summary
Gyre Therapeutics announced the acquisition of Cullgen Inc. on May 4, 2026, a significant strategic move. For the first quarter of 2026, the company reported a net loss attributable to common stockholders of $(8.69) million, a shift from a net income of $2.70 million in the prior year period, despite a 2.1% increase in revenues to $22.52 million. The loss was primarily driven by substantial increases in research and development, selling and marketing expenses, and $2.55 million in merger-related transaction costs. However, the company generated $3.18 million in net cash from operating activities, improving from a cash outflow in the previous year.
Key Highlights
- Acquired Cullgen Inc. on May 4, 2026, making it a wholly owned subsidiary.
- Reported a net loss attributable to common stockholders of $(8.69) million for Q1 2026.
- Basic net loss per share was $(0.10) for Q1 2026, compared to $0.03 income per share in Q1 2025.
- Revenues increased 2.1% to $22.52 million for Q1 2026 from $22.06 million in Q1 2025.
- Research and development expenses surged 117.7% to $6.74 million in Q1 2026.
- Selling and marketing expenses rose 30.4% to $14.14 million in Q1 2026.
- Incurred $2.55 million in transaction costs during Q1 2026, related to the merger.
- Net cash provided by operating activities was $3.18 million for Q1 2026, up from $(0.13) million used in Q1 2025.
Price Impact
More from GYRE